United Therapeutics CORP Form 4 insider transactions

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed multiple sales of common stock on June 28, 2024, and July 1, 2024, through a pre-arranged 10b5-1 trading plan.

Jan Malcolm, a new director at United Therapeutics, reports the acquisition of stock options and restricted stock units as part of the Non-Employee Director Compensation Program.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Director Tommy G. Thompson exercised stock options and sold shares of United Therapeutics Corp on June 26, 2024.

Director Nilda Mesa sold 266 shares of United Therapeutics Corp (UTHR) on June 25, 2024, at a price of $318.5784 per share.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 24 and 25, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 20 and 21, 2024, under a pre-arranged 10b5-1 trading plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, reports exercising share tracking awards and disposing of common stock on June 20, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on June 17 and 18, 2024.

Christopher Causey, a director at United Therapeutics, exercised stock options and sold shares on June 18, 2024.

Director Judy D. Olian sold 1,700 shares of United Therapeutics Corp (UTHR) on June 17, 2024, at a price of $295.4267 per share.

Director Christopher Patusky reports the acquisition and disposal of United Therapeutics Corp (UTHR) common stock on June 17, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed a series of stock option exercises and sales on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, CEO of United Therapeutics, executed a stock option exercise and sale of common stock on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Causey, a director at United Therapeutics, exercised stock options and sold 2,000 shares of common stock on June 13, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 11 and 12, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on June 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 30 and 31, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 28 and 29, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 23 and 24, 2024, under a pre-arranged 10b5-1 trading plan.

Director Martine Rothblatt exercised stock options and sold shares of United Therapeutics Corp (UTHR) on May 22, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock option exercises and sales on May 20 and May 21, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, a director at United Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Director Christopher Causey exercised stock options and sold 2,000 shares of United Therapeutics Corp (UTHR) on May 15, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics Corp, reports the acquisition and disposal of common stock and share tracking awards on May 15, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 14 and 15, 2024, under a pre-arranged 10b5-1 trading plan.

Christopher Patusky, a director at United Therapeutics Corp, exercised stock options and sold shares on May 14, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on May 10 and May 13, 2024, under a pre-arranged 10b5-1 trading plan.